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236 The Journal of Thoracic and Cardbjective: Our objective was to define the role of a new 1318-nm Nd:YAG laser for
obe- and parenchyma-saving resection of multiple lung metastases.
atients and Methods: From January 1996 to December 2003, a total of 3267
odules (10/patient) were removed from 328 patients (164 men/164 women, mean
ge 61 years). Criteria for eligibility were expanded to any primary tumors with no
pper limit of metastases given. All parenchymal resections were performed with a
ew 1318-nm Nd:YAG laser whose effect on lung tissue differs significantly from
hat of the 1064-nm wavelength owing to a 10-fold higher absorption in water and
ne-third extinction in blood. In 93%, precision laser resection was achieved. The
obectomy rate was only 7%.
esults: Pathologic examination revealed 2546 metastases (8/patient) and lymph
ode disease in 19%. Complete resections (R0) were achieved in 93% of 177
atients undergoing unilateral procedures with a mean of 3 metastases (range
%-29%) and 75% of 151 patients having bilateral operations with a mean of 13
etastases (range 2-124). The 5-year survival after R0 was 55% for solitary
odules, 41% for all patients, 28% for 10 metastases, and 26% for 20 or more
etastases resected. Outcome was significantly poorer after incomplete resection
7%). No 30-day mortality was observed. Major postoperative complications in-
luded prolonged air leaks (n  2), intrapleural bleeding (n  2), and late
neumothorax (n  2); all were treated successfully with a chest tube.
onclusion: This new 1318-nm Nd:YAG laser facilitates complete resection of
ultiple bilateral centrally located metastases and thus is lobe sparing. Resection of
0 or more metastases is reasonable because long-term survival was significantly
etter than that observed with incomplete resection.
 
he therapeutic value of pulmonary metastasectomy has been gradually
cepted and nowadays this operation is routinely performed in many depart-
ments, but only in carefully selected cases and commonly for 5 or fewer
etastases.1-4
So that a more extensive database would be available for areas of major contro-
ersy (the selection of patients, the maximum number of resectable metastases, the
ole of bilateral surgery, the significance of secondary lymph node metastases, and
urgical techniques), the International Registry of Lung Metastases (IRLM) was
aunched in 1990 and the results of 5206 cases were reported in 1997.4 The study
onfirmed that metastasectomy in general is a potentially curative treatment, even
or patients having redo surgery and for those with higher numbers of metastases.
owever, despite these encouraging results, a classification of prognostic groups
as offered, leading again to more restricted selection of patients.
With the results of our institution’s study we want to report on a new 1318-nmavelength Nd:YAG laser system that we have developed. This laser facilitates
iovascular Surgery ● June 2006
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G
TSobe-sparing precision resection of a large number of me-
astases and thus improves complete resection, which is the
ost important prognostic factor after surgery. As a result
f systematic lymph node dissection in all patients, we can
ffer additional results for metastasectomy with concomi-
ant lymph node disease in patients with epithelial primary
umors in a clinical setting previously considered to have a
oor prognosis. Furthermore, we want to encourage progres-
ive expansion of eligibility of patients for salvage surgery
nd strengthen the role of pulmonary metastasectomy in the
nterdisciplinary treatment of metastatic disease.
atients and Method
cientific Background
fter studying lung tissue determinants in 1986,5,6 we recognized
hat lung parenchyma with 80% water content, very low tissue
ensity (one fifth of liver), and high shrinking capacity owing to
lveolar air content demonstrated qualities very well suited to
hotothermal laser resection. The challenge to gain benefit for all
ypes of parenchymal lung resections was to find and add the best
aser parameters. Our first experiments showed that only an Nd:
AG laser can offer the intended combination effect of cutting and
oagulation. In contrast to the 1064-nm standard wavelength ex-
lusively offered by the industry at that time, we suspected the
econd wavelength of 1318-nm to be superior owing to its 10 times
igher absorption in water and still sufficient laser light scatter-
ng.7,8 In fact, this wavelength provided significantly better cut
nd coagulation qualities and caused strong tissue shrinking as a
elcome side-effect reinforcing mechanical stability of the periph-
ry of the resection area and thus sealing off air leaks deep in the
enter of lobes. More details of the biophysical background and
evelopment of this laser device were previously published by the
rst author (A.R.).5,6,9,10 Parenchymal laser resection techniqu
an actually be seen in video sequences via the Internet.11
ndications for Laser Metastasectomy
riteria for progressively expanded eligibility for laser metasta-
ectomy are indicated in Table 1, whereas exclusion criteria ar
ame as for thoracic surgery generally. After evaluation for com-
lete resection of the original tumor and other extrathoracic me-
astases, we accepted any primary malignancy with single or
ultiple, synchronous or bilateral lung metastases. No limit to the
umber of metastases was given, but assessment of functional and
echnical resectability by a thoracic surgeon experienced with this
pecial laser technique was mandatory as well as routine exami-
ation with a flexible bronchoscope. Furthermore, patients with
uspected N2 lymph node disease in their preoperative computed
omographic scans had transtracheal, transbifurcal, or transesoph-
geal biopsy of lymph nodes with combined rigid and flexible
ronchoscopy or endosonography. Only patients with unilateral
2 disease and suspected resectability were included. In case of
Abbreviations and Acronyms
IRM International Registry of Lung Metastasesubcarinal lymph nodes, only solitary nodules were accepted. c
The Journal of Thoracice
All sublobar laser resections and combined lobectomies
lobectomy rate 7%, bronchoangioplastic procedures included)
ere performed via an anteroaxillary muscle- sparing approach
staged 3 to 4 weeks if bilateral) beginning with the side consid-
red to be the more difficult. Parenchymal resections were exclu-
ively performed by 1318-nm Nd:YAG laser. No bioadhesives or
tapling devices were used because even for small peripheral
odules the parenchyma-saving effect is impressive. The loss of
issue after precision laser resection was measured to be up to
-fold smaller than with stapler resections. During surgery every
alpable nodule down to 1 mm in size was resected by “precision”
aser resection with a 3-mm tumor margin and sent for pathologic
xamination. One important strength of this laser technique is the
asy optical control of the tumor margin during bloodless paren-
hymal resection and the fact that an additional laser necrosis zone
f minimal 0.5-cm diameter remains in situ with the patient5,9,11
hus, frozen section examinations were necessary only in selected
ases when infiltration of great bronchovascular structures was
uspected. Resection margins of any nodule removed were defi-
itely analyzed by our pathologist, who describes the amount of
ormal lung tissue around the metastasis resected. In the rare case
f a final pathology report indicating an incomplete circumferen-
ial ring of normal lung tissue around the removed metastasis (ie,
n case of R1 resection), the follow-up is continued by patient
bservation, also owing to the previously mentioned fact of the
dditional laser necrosis zone of 0.5-cm size of the in situ site.
Systematic lymph node sampling according to Naruke’s
lassification11a was mandatory; in cases of N2 disease, media-
al dissection was performed. Resection was considered com-
lete if no macroscopic chest disease remained in situ and
esection margins were negative for tumor. In the presence of
ymph nodes, they had to be resected with no gross or microscopic
ABLE 1. Criteria for progressively expanded eligibility for
aser metastasectomy
riteria of eligibility for
etastasectomy Exclusion criteria
Any primary malignancy ● Performance status 80%
Karnofsky
Primary completely resected ● FEV1 80% for bilateral
resections, FEV1 70% for
unilateral resections
No extrathoracic metastases
incompletely resected
● Severe cardiac disease or
other high risk factors
Unilateral and bilateral
metastases
No limit to number (the limit
is functional and technical
resectability)
Lymph node involvement up
to N2 unilateral
Previous chemotherapy
EV1, Forced expiratory volume in 1 second.apsular escape.
and Cardiovascular Surgery ● Volume 131, Number 6 1237
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G
TSemographics and Procedures
rom January 1996 to December 2003, a total of 328 patients, 164
en and 164 women with a mean age of 61 years (range 20-80
ears) were eligible for enrollment in this single center and insti-
utional review boarded retrospective study. They underwent 484
horacotomies. A mean hospital stay of 10 days was observed,
omparable with that of German thoracic departments. Complete
ollow-up (mean 31 months, range 1-198 months, median 22.5
onths) was achieved for all patients. In only 23 patients (7%)
ere we unable to clarify whether the recurrence of metastases
as pulmonary or extrathoracic (or both) and thus the differenti-
tion of recurrence remained unclear. A total of 3267 nodules
10/patient) were removed. Despite the 40% central location of
etastases, in 93% precision sublobar laser resection was achieved.
n only 7% a lobectomy or a bronchoangioplastic procedure was
ecessary. Pathologic examination revealed 2546 metastases (8/
atient), 20% benign lesions, and simultaneous lymph node me-
astases in 19%. Under these conditions, complete resection was
chieved in 93% of 177 patients undergoing unilateral procedures
ith a mean of 3 metastases resected per patient (range 1-29) and
5% of 151 patients having bilateral operations with a mean of 13
etastases removed per patient (range 2-124). Causes of incom-
lete resections in 50 patients (15%) were unexpected intraopera-
ive miliary spread of metastases, unresectable lymph node dis-
ase, or pleural dissemination of the tumor excluding the patients
rom further surgery. For 22 patients, incomplete resection was the
esult after the first surgery and the operation for the second side
as not performed. Ninety-one percent of the primary tumors were
pithelial tumors (carcinoma), with kidney cancer as the leading
rimary tumor (n  112) followed by colorectal (n  91) and
reast cancer (n 35). Sarcoma and melanoma were found in only
% and 3%, respectively. Table 2 shows the distribution o
ary tumors.
esults
or multiple sublobar laser resections of lung metastases
very low perioperative and postoperative morbidity was
bserved. Even in combination with lobectomies and
ronchoplastic procedures (7%), no 30-day mortality oc-
urred and no patient died in the hospital after metasta-
ectomy. Major postoperative complications included 2
ABLE 2. Distribution of primary cancers in our series
Site No. of patients (%)
Kidney 112 (34%)
Colorectal 91 (28%)
Breast 35 (11%)
Sarcoma 15 (4%)
Gynecologic 13 (4%)
Bronchogenic 12 (4%)
Melanoma 11 (3%)
Head/neck 12 (4%)
Other 27 (8%)
Total 328 (100%)ases of prolonged air leak (7 days in patients with 40 and s
238 The Journal of Thoracic and Cardiovascular Surgery ● Jun-
0 metastastatic lesions resected, respectively), 2 cases of
ntrapleural bleeding that required decortication at the time
f metastasectomy owing to previous surgery, and 2 cases
f late pneumothorax (4 and 6 weeks after discharge) in
oung patients during sports activities. All complications
ere successfully treated by chest tube; there was no need
or reoperation. No further delayed air leaks or pneumotho-
aces were observed with a maximal follow-up time of 7
ears.
Overall survival for all cell types was 81%, 53%, and
5% for 1, 3 and 5 years, respectively. The most important
rognostic factor for survival was completeness of resection
Figure 1). The 1-, 3-, and 5-year survivals for pa
aving complete resection, with a mean of 8 metastases
emoved per patient, were 85%, 59%, and 41% versus 60%,
3%, and 7% for those having incomplete resection (P 
0001). No statistical significance (P  .2) was found when
omplete resections including regional lymph nodes (R0
1/2) were compared with complete resections without
ymph node disease (R0 N0) (Figure 2).
Compared with unilateral procedures (Figure 3), a 
ificant higher number of metastases were resected with
taged bilateral operations (mean 3 versus 13 metastases)
ssociated with a decrease of complete resection rate (93%
ersus 75%), but 5-year survivals of 36% showed no sig-
ificantly poorer outcome for patients after completely re-
ected bilateral metastases.
There is a widespread acceptance that the number of
etastases is another important prognostic factor implicat-
ng an upper limit.2,12,13 Figure 4 and Table 3 demonstrat
igure 1. Overall survival after complete (R0) resection versus
ignificantly poorer incomplete (R1/R2) resection (P  .0001).
quares  R0; bullets  R1/R2.urvival of patients after complete resection of metastases in
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G
TSifferent groups from 1 up to 20 and more in comparison
ith the results published by the IRLM.4 In contrast to 1
enters of this Registry describing significance in survival
ven between 1 and 2 metastases, our statistical analysis
ound no significance between solitary and multiple metas-
ases up to a total of 9 (P  .52). Just with the group of 10
o 19 metastases, a statistically significant difference com-
ared with survival with solitary metastases was found (P
002). But complete resection of 20 or more metastases still
emonstrates significantly better outcome than the poor 7%
-year survival for incomplete resection. Solitary metastasis
as found in only 28% in our series. In contrast, nearly half
f our patients had 4 or more metastases, 21% had 10 or
igure 2. Overall survival after complete resection of metastases
ith (R0 N1/2) or without (R0 N0) lymph node disease (no signif-
cance P  .2). Squares  R0 N0; bullets  R0 N1/N2.
igure 3. Overall survival after complete resections. Unilateral
ersus staged bilateral surgery for lung metastases (no signifi-
ance P  .35). Squares  R0 unilateral; bullets  R0 bilateral. w
The Journal of Thoracicore, and 9% of our patients had 20 or more metastases
ollowed by a 5-year survival of 26%.
Follow-up for all patients was complete except for 7% in
hom we could not define the site of recurrence. For the rest
f the patients, recurrence rate after complete resection was
0% with a mean of 12 months or a median of 9 months to
ecurrence, respectively. Twenty-nine percent of these pa-
ients had extrathoracic, 31% pulmonary and extrathoracic,
nd 40% had isolated recurrence to the lung. Thirty-two per-
ent of patients with pulmonary recurrence and 10% of
hose with extrathoracic and pulmonary recurrence had
edo surgery after complete resection of their extrathoracic
etastases. With respect to the leading primary tumors, a
early constant percentage of patients (35% renal cell car-
inoma, 36% colorectal, 32% breast cancer) remained with-
ut recurrence and had a disease-free course. Distribution
f unilateral versus bilateral thoracotomies among these
igure 4. Influence of the number of completely resected metas-
ases on survival. Dark squares  1 metastasis (n  78); bullets
2 to 5 metastases (n  106); stars  6 to 9 metastases (n  37);
iamonds  10 to 19 metastases (n  32); light squares  20 or
ore metastases (n  25).
ABLE 3. Five-year survival for different number of com-
letely resected metastases in our series (R0 n  278,
ompared with IRLM4)
o. of
etastases
IRLM Coswig
5-y survival% 5-y survival n %
1 47 43 78 28 55
2-3 27 34 64 23 33
4 26 27 136 49 36
Total 100 278 100
10 9 26 57 21 28
20 3 — 25 9 26
he International Registry of Lung Metastases (IRLM) number of patients
as not available.
and Cardiovascular Surgery ● Volume 131, Number 6 1239
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G
TSisease-free patients was comparable, and the highest num-
er of resected metastases was 20 for renal cell carcinoma,
for colorectal, and 40 for breast cancer.
iscussion
t the end of the 1980s and the beginning of the 1990s,
ome centers tried to introduce the Nd:YAG laser for pa-
enchymal resection, but the 1064-nm wavelength available
t that time could not provide sufficient cutting and coagu-
ation qualities to handle extended resection to the center of
 lobe.14-16 Thus only a few patients were enrolled in stu
nd further reports on laser surgery to the lung dried up. We
nitiated a new start in this by identifying the 1318-nm
avelength to provide simultaneously the 3 qualities (cut,
oagulate, seal) needed for deep parenchymal lung resection
ue to a 10-fold higher absorption in water and only one-
hird extinction in blood. A laser device delivering sufficient
ower output to generate this 1318-nm wave length was
eveloped in our institution.5,6,10 Since 1996 the significan
umber of 328 patients with 484 thoracotomies performed
ere eligible for us to report on metastasectomy using this
ew laser technology. Owing to improvement of surgical
echnique, we aggressively expanded the criteria of eligi-
ility to include any malignant primary tumor with unilat-
ral resectable N2 disease and gave no definitive limit to the
umber of metastases, a radical approach not yet reported
y other authors. Repeated palpation of the completely
eflated lung and laser resection of any nodule identified by
n experienced thoracic surgeon was mandatory to gain
omplete resection. Under these conditions, 3267 lesions
10/patient) were removed and pathologic assessment re-
ealed 2546 metastases (8/patient). Our results are dis-
ussed with recent publications but with special respect to
hose published by the IRLM, representing 18 renowned
enters of thoracic surgery and the greatest database of
nformation available for metastasectomy. Despite the high
umber of metastases resected and the presence of 19%
ymph node metastases, a similar rate of complete resection
85% vs 88%) was observed. Besides the controversy of
election of patients, the resection of multiple, large, hilar,
nd centrally located metastases is first of all a matter of
urgical technique. When electrocautery, clamps, or staplers
re used, the number of metastases that can be resected is
imited and the lobectomy rate using these techniques is
requently reported as 20% to 25%,1,3,4 3-fold higher than i
ur series. In a recently published study, Murthy and asso-
iates18 had calculated the probability of incomplete res-
ion in relation to the number of metastases for the use of
onventional technique. The likelihood of incomplete resec-
ion reached 80% when there were 6 metastases and ap-
roximately 100% when there were 8 nodules identified on b
240 The Journal of Thoracic and Cardiovascular Surgery ● Junreoperative chest computed tomography. Murthy and
olleagues18 emphasized that the preoperative account 
ulmonary nodules accurately reflected the number of
odules resected. These actual results are well suitable to
iscuss the advantages of this laser resection technique
ith a mean of 10 nodules and a maximum of 124
etastases completely resected in 85% of the patients in
ur series. We found the main cause of incomplete re-
ections (15%) to be inaccuracy of computed tomo-
raphic scans of candidates with preoperatively known
igh numbers of metastases. In these cases, intraopera-
ive unexpected miliary spread of metastases or pleural
issemination of the tumor and unresectable lymph node
isease were the reasons for incompleteness. In 93%
ersus 75% (IRLM), precision sublobar laser resections
p to segmental resection were performed according to
he size of the metastasis, with a maximum of 8 cm. This
igh percentage of limited resections together with a
ignificant reduction of lobectomy rate (7% vs 22%)
ndicates the parenchyma-saving effect of this laser
echnique.
Complete resection is the most important prognostic
actor and thus functional and technical resectability should
e the central criteria of eligibility. When complete resec-
ion is gained, a 5-year survival of 41% is observed, all cell
ypes included, and no significantly poorer outcome was
een for associated lymph node disease and bilateral resec-
ions. In contrast to many other studies, our study found no
ignificance for the outcome between patients with solitary
nd multiple (up to 9) metastases.1-4
Patients with a disease-free interval greater than 36
onths showed significantly better survivals (55%), but
atients with a mean of 8 synchronous metastases (12
onths) who underwent complete resection still had 5-year
urvival of 34%. In summary, we want to assert that the
rognostic value of traditional factors (solitary, disease-free
nterval, number) is diminished if the technical ability to
erform a complete resection can be improved. We found
hese arguments further confirmed with a 5-year survival of
6% for patients with 4 or more, 28% for 10 or more, and
nally 26% for 20 or more metastases completely resected.
We conclude that this new 1318-nm laser system im-
roves any kind of lung parenchymal resection, facilitates
omplete resection of multiple bilateral and centrally lo-
ated metastases, and thus is lobe sparing. Owing to our
esults, we believe that these resections are reasonable and
orthwhile. For the immediate future we expect to have a
ufficient number of patients enrolled in our study to allow
s to evaluate results according to cell type. And because a
rowing number of centers having taken over this technol-
gy, we should be able to start a prospective randomized
rial analyzing the value of multimodality treatment in com-
ination with a laser metastasectomy.
e 2006
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G
TSimitations
his study is limited by several factors: (1) comprises the
linical experience of a single institution and a new tech-
ology; (2) lack of differentiation according to the cell type;
3) lack of preoperative positive emission tomography–
omputed tomography scan screening for extrathoracic spread
f metastases; (4) 91% epithelial primary tumors estimated
o have poorer prognosis; (5) selection of patients, the
ajority initially being classified as having unresectable
isease.17
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r David R. Jones (Charlottesville, Va). I wish to congratulate Dr
olle and his colleagues from Dresden on a remarkable series with
xcellent clinical results of 328 patients with more than 2200
esected metastases. It appears as though this technique affords the
urgeon the ability to actually preserve lung parenchyma and
dditionally potentially increases the number of patients who may
e eligible for metastasectomy, even those who have a significant
umber of bilateral metastases. I have several questions for Dr
olle, which I will ask one at a time.
I was surprised and impressed that the rate of lobectomy was
-fold less than what was seen in the international registry. Do you
nd that your need to perform a lobectomy is now based more on
he central location of the lesion or is it based more on the fact that
here are so many lesions in a given lobe that you in fact have to
erform a lobectomy?
Dr Rolle. The lobectomy rate could be lowered as much as 7%
n this series compared with other series, in which the lobectomy
ate is 20% to 25%. The cases in which we have to do a lobectomy
nvolve very great metastases located with the central vessels.
hese are the only cases in which we have to perform lobectomy
r bronchoplastic surgery.
Dr Jones. Part of the premise of using the 1318-nm laser is that
ou are actually preserving lung parenchyma. Do you have any
ulmonary function data on these patients before and then after
etastasectomy? Were you able to make a retrospective compar-
son between an older group of patients who had staples used for
heir metastasectomy and your current, laser-treated group to see
hether you actually are preserving lung parenchyma?
Dr Rolle. That is a very interesting question. We had measure-
ents of all ventilatory parameters preoperatively and postopera-
ively. I don’t have the statistical analysis yet, but we will do it. We
ould see that after 3 months and 6 months, most of the patients
ho have had resection of more than 30 or 40 metastases returned
o a lung function between 80% and 90% of the preoperative value.
Dr Jones. Finally, how do you handle the more central aspect
f this “sculpted” resection, if you will, of the metastatic lesions as
ou begin to approach the larger vessels centrally in the segmental
ronchi?
Dr Rolle. If we have to operate very close to the central
essels, we secure it by vessel-loop. However, with some experi-
nce, we can approach very close even to the hilar structures. For
xample, if we have a resection with metastases of a diameter of
or 7 cm, then we come to the segmental level and we finally
esign ourselves to suturing the segmented bronchus and seg-
ented artery. This is necessary. But the advantage is that one can
ncologically safely go around the parenchymal tissue and come
p to this level within the lobe.
Dr Joseph Zwischenberger (Galveston, Tex). When I first
eard of Dr Rolle’s work on the new laser 4 years ago in Germany,
said to myself, this is important, if true. Since that time I have
valuated this technology in my own laboratory, Dr Tom Daniels
resented work at this meeting validating this technology, and now
r Rolle is presenting 5-year follow-up on metastasectomy. What
can say is that this work is important and true. What I ask Dr
olle is, how do you plan on allowing distribution of this newechnology?
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TSDr Rolle. We have some progress in Europe. In the meantime,
ore than 35 centers have taken over this technology in Germany
nd Austria and Italy and so on. The next step for this country is
pproval by the Food and Drug Administration. I hope that the
ompany will come over with this in the near future.
Dr Zwischenberger. Excellent work.
Dr Adelheid End (Vienna, Austria). Do you perform medias-
inal lymphadenectomy in all patients and how does it influence242 The Journal of Thoracic and Cardiovascular Surgery ● JunDr Rolle. We did systematic lymphadenectomy. I think all
hese metastasectomies should go through the same techniques
hen with bronchocarcinoma. We did systematic lymph node re-
ection in every patient. I will give you the numbers: 14% of those
aving complete resections had lymph node disease and 85%, N2
isease. We were surprised that the results were very good with
omplete resections. So we extended the indication and included
atients with unilateral N2 disease, not with bilateral disease. Theyour strategy of adjuvant therapy? are not operated on.e 2006
